TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03159416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
Study: NCT01983475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
Study: NCT03070951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Study: NCT01983475

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (identical Denosumab volume of normal saline)
Description: The placebo group will receive the identical volume of normal saline at parallel time points.
Study: NCT04056416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedBIKE
Description: A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
Study: NCT03607214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal spray~Film Sequence
Study: NCT03070951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match OBE2109
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Add-back
Description: Placebo to match Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Add-back
Description: Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily
Study: NCT01122641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets
Study: NCT03919396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath-O orthokeratology lenses
Description: Specially designed rigid gas permeable lenses which~1. reshapes corneal profile for myopia control~2. has higher elasticity compared to traditional lens material.
Study: NCT01952132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS643762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03796728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT™ with Lidocaine
Description: Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
Study: NCT03667482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered at 500 mg/m\^2 intravenously every other week on Days 1 and 15 of each cycle, with a window of up to 3 days before the scheduled date. In an effort to prevent a hypersensitivity reaction, it is recommended that all patients pre-medications, hydration, and anti-emetics will be given according to institutional guidelines and/or per treating physician discretion.
Study: NCT02262585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 277 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 277 capsule
Study: NCT03284463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
Study: NCT01791244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif®
Study: NCT04166812

Intervention type: DIAGNOSTIC_TEST
Intervention: oscillometry
Description: assessment of peripheral airway resistance using oscillometry

Intervention type: DIAGNOSTIC_TEST
Intervention: oscillometry
Description: assessment of peripheral airway resistance using oscillometry

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout testing
Description: assessment of ventilation heterogeneity using multiple breath washout testing

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout testing
Description: assessment of ventilation heterogeneity using multiple breath washout testing

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: assessment of lung function using spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: assessment of lung function using spirometry

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: assessment of lung function using body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: assessment of lung function using body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: fractional exhaled nitric oxide
Description: assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide

Intervention type: DIAGNOSTIC_TEST
Intervention: fractional exhaled nitric oxide
Description: assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide

Intervention type: DIAGNOSTIC_TEST
Intervention: transfer factor
Description: assessment of gas transfer using single breath transfer factor for carbon monoxide

Intervention type: DIAGNOSTIC_TEST
Intervention: transfer factor
Description: assessment of gas transfer using single breath transfer factor for carbon monoxide

Intervention type: DIAGNOSTIC_TEST
Intervention: health status
Description: assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])

Intervention type: DIAGNOSTIC_TEST
Intervention: health status
Description: assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire \[SGRQ\], COPD Assessment Test \[CAT\])

Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)

Intervention type: DIAGNOSTIC_TEST
Intervention: computed tomography
Description: assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)

Intervention type: DIAGNOSTIC_TEST
Intervention: induced sputum
Description: various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)

Intervention type: DIAGNOSTIC_TEST
Intervention: induced sputum
Description: various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
Study: NCT02341560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection - 1.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection - 3.0 mg

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection Procedure
Description: Sham Procedure
Study: NCT01368588

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo RT using IMRT or 3D-CRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-pelvic radiotherapy (WPRT)
Description: Undergo whole-pelvic radiotherapy (WPRT)
Study: NCT02647099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02145143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: serial 124I PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyrotropin alpha
Study: NCT04148807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Walking with Gait Retraining
Description: A progressive walking program with gait retraining will be performed on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Walking Program
Description: A progressive walking program will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
Study: NCT03402542

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy
Study: NCT01009541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: 82.5 mg controlled release tablet administered once daily for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: 165 mg controlled release tablet administered once daily for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg
Description: 330 mg controlled release tablet administered once daily for three days.

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 150 mg
Description: 150 mg immediate release capsules administered every 12 hours for three days
Study: NCT04479085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing intervention
Description: It includes individual trainings for the regulation of the home environment,~give a booklet~to reinforce education and to give anti-allergic bedding sets.
Study: NCT04494256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB105
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT03259230

Intervention type: OTHER
Intervention: Blood Draws

Intervention type: OTHER
Intervention: Blood Draws

Intervention type: OTHER
Intervention: Data Collection

Intervention type: OTHER
Intervention: Data Collection
Study: NCT00113841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bioperine
Description: 5 mg (Tablets) orally twice daily
Study: NCT01476670

Intervention type: OTHER
Intervention: Monitoring
Description: Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
Study: NCT02987231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: CAF
Description: Periodontal plastic surgery for root coverage by the trapezoidal flap

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES
Description: Local electric stimulation for 120 seconds, once a day for a week

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
Study: NCT01651481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair and Xyzal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair and Xyzal
Study: NCT02253225

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
Study: NCT01110824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril and carvedilol
Description: Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
Study: NCT00377520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 900 mg/m2, intravenous (IV), every 21 days, until disease progression
Study: NCT01476722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist multipurpose disinfecting solution
Description: FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
Study: NCT06045312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Comparison of the effectiveness of peer or adult education to adolescents with asthma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Comparison of the effectiveness of peer or adult education to adolescents with asthma
Study: NCT01155713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study: NCT02528084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga
Description: patients watch and follow an online yoga video.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard exercises
Description: patients watch and follow an online standard exercises video.
Study: NCT02644486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dosage Sevelamer Carbonate + Irbesartan
Description: Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dosage Sevelamer Carbonate + Irbesartan
Description: Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan 300mg/d
Study: NCT03901417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore (Non-ablative Fractional Laser)
Description: In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)
Description: In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
Study: NCT01798693

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-nutrient Blend
Study: NCT01718379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide:10 mg per day during 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta: 60,000 Units/week.
Study: NCT02506894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: magnesium sulfate will be given for 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride solution
Description: normal saline will be given as intravenous drip over 24 hours
Study: NCT00079326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04213950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rabies PEP quality improvement bundle
Description: The rabies PEP quality improvement bundle consists of (1) electronic health record enhancements to support rabies PEP treatment selection, administration, and discharge process; (2) education to ED staff on rabies PEP; and (3) education to patients on rabies PEP and follow-up care.
Study: NCT00742053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG-guided PICC placement
Description: Patients undergoing PICC placement will have ECG data collected as a function of tip location.
Study: NCT04308395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patidegib Topical Gel, 2%
Description: Patidegib Topical Gel, 2%
Study: NCT03829085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EARLY ORAL REFEEDING
Description: the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
Study: NCT01422096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if \> 37.5 kg im once
Study: NCT01182636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene
Description: 0.1% Topical Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin®
Description: 0.1% Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel Base
Study: NCT02843230

Intervention type: RADIATION
Intervention: Avastin

Intervention type: RADIATION
Intervention: Avastin

Intervention type: RADIATION
Intervention: Avastin

Intervention type: RADIATION
Intervention: Lomustine

Intervention type: RADIATION
Intervention: Temozolomide

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRI

Intervention type: DEVICE
Intervention: MRS

Intervention type: DEVICE
Intervention: MRS

Intervention type: DEVICE
Intervention: MRS

Intervention type: DEVICE
Intervention: DSC

Intervention type: DEVICE
Intervention: DSC

Intervention type: DEVICE
Intervention: DSC
Study: NCT02099851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid body ablation (Cibiem)
Study: NCT00214045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Cystoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Cystoscopy